

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Link-Asia International MedTech Group Limited**

**環亞國際醫療科技集團有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1143)**

### **DELAY IN DESPATCH OF CIRCULAR**

Reference is made to the announcements (the “**Announcement(s)**”) of Link-Asia International MedTech Group Limited (the “**Company**”) dated 13 September 2022 and 14 September 2022 in relation to, among others, the Subscription and the Whitewash Waiver. Unless the context requires otherwise, capitalised terms used herein shall have the same meanings as defined in the Announcements.

As disclosed in the Announcement, pursuant to Rule 8.2 of the Takeovers Code, a circular (the “**Circular**”) containing, among other things, (i) details of the Subscription and the Whitewash Waiver; (ii) the recommendation of the Independent Board Committee to the Independent Shareholders; (iii) the letter of advice from independent financial adviser to the Independent Board Committee in relation to the Subscription and the Whitewash Waiver; and (iv) a notice convening the EGM is required to be despatched to the Shareholders within 21 days from the date of the Announcement dated 13 September 2022, that is, on or before 5 October 2022.

As additional time is required for the Company to finalise certain financial information of the Group, including the indebtedness statement of the Group, to be included in the Circular, the Company has applied for the consent of the Executive for an extension of the deadline for the despatch of the Circular to a date falling on or before 26 October 2022. The Executive has indicated that it is minded to grant such consent.

By order of the Board  
**Link-Asia International MedTech Group Limited**  
**Lin Dailian**  
*Chairman and executive Director*

Hong Kong, 5 October 2022

*As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Wang Guozhen and Ms. Lin Xiaoshan as executive Directors; Mr. Li Huiwu, Mr. Yang Weidong and Mr. Chak Chi Shing as independent non-executive Directors.*

*The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.*